1,1'-(methylenedi-p-phenylene)bismaleimide

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

From 22 May to 05 October 2012

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Remarks:

The study was run according to OECD test guidelines and in compliance with GLP; on thia basis it is considered reliable without restrictions.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2012

Report date:

2012

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

1,1'-(methylenedi-p-phenylene)bismaleimide

EC Number:

237-163-4

EC Name:

1,1'-(methylenedi-p-phenylene)bismaleimide

Cas Number:

13676-54-5

Molecular formula:

C21H14N2O4

IUPAC Name:

1-(4-{[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl]methyl}phenyl)-2,5-dihydro-1H-pyrrole-2,5-dione

Constituent 2

Reference substance name:

N,N'-Diphenylmethane bismaleimide

IUPAC Name:

N,N'-Diphenylmethane bismaleimide

Constituent 3

Reference substance name:

BMI

IUPAC Name:

BMI

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

Details on test material:

Batch number: 1K72J
Purity: 94.2%

Test animals

Species:

rat

Strain:

Crj: CD(SD)

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Age at study initiation: (P) 70 days
- Weight at study initiation: (P) Males: 339-399 g; Females: 225-277 g
- Housing: Animals were housed inside a barriered rodent facility.
- Diet (e.g. ad libitum): The animals were allowed free access to a standard rodent diet except overnight before routine blood sampling.
- Water (e.g. ad libitum): Potable water taken from the public supply was freely available via polycarbonate or polypropylene bottles fitted with sipper tubes.
- Acclimation period: five days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 23°C.
- Humidity (%): 40 to 70%
- Photoperiod (hrs dark / hrs light): a cycle of 12 hours continuous light and 12 hours continuous dark per 24 hours

IN-LIFE DATES: From: 2 July 2012 To: Males 7 August 2012, Females 18 August 2012

No additional data

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: 1% Methylcellulose

Details on oral exposure:

PREPARATION OF DOSING SOLUTIONS: The test substance was prepared for administration as a series of graded concentrations in the vehicle. Starting with the lowest concentration, the required amount of the test substance was weighed, transferred to a suitably sized mortar and ground to a fine powder using a pestle. Small amounts of the vehicle were added and mixed with the test substance to form a smooth paste. The suspension was poured into a measuring cylinder which had been wetted with the vehicle. The mortar was rinsed thoroughly with the vehicle and the rinsed residue was added to the measuring cylinder. The required volume was achieved by addition of the remaining vehicle and the suspension was transferred to a beaker and mixed using a high shear homogeniser until homogenous. During magnetic stirring, the suspension was transferred to the final containers, via syringe. Remaining concentrations were prepared in ascending group order using the same method.

VEHICLE
- Concentration in vehicle: 10, 30, 100 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg

No additional data

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

Apparatus and instrumentation
High performance liquid chromatograph (HPLC)

Sample process
A representative sample of test formulation (nominally 1 mL, accurately weighed) was dissolved using ultrasonic vibration in a suitable volume of diluent. The extract was diluted using mobile phase to provide a solution containing test substance at an expected concentration within the range 1.0 μg/mL to 2.0 μg/mL.
The concentration of the test substance in the final solution was quantified by high performance liquid chromatography using UV detection as detailed in the chromatographic section.

Typical chromatographic conditions
Analytical column: Agilent Poroshell 120EC C18, 2.7 μm, 100 × 4.6 mm
Column temperature: 40°C
Mobile phase: Acetonitrile/water/acetic acid 45/55/0.3 v/v/v
Flow rate: 1.00 mL/minute
Detector wavelength: UV, 235 nm
Injection volume: 5 μL
Run time: 5 minutes
Approximate retention time: 3.8 minutes

The mean concentrations of the test substance in test formulations analysed for the study were within +10/-15% of nominal concentrations, confirming accurate formulation.

Duration of treatment / exposure:

4 weeks

Frequency of treatment:

Males were treated daily, two weeks before pairing up to necropsy after a minimum of five consecutive weeks. Females were treated daily for two weeks before pairing, throughout pairing and gestation, until Day 6 of lactation.

Doses / concentrations

Remarks:

Doses / Concentrations:
100, 300 or 1000 mg/kg/day
Basis:
actual ingested

No. of animals per sex per dose:

10 males and 10 females per dose

Control animals:

yes, concurrent vehicle

Details on study design:

None stated

Positive control:

None stated

Examinations

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Animals were inspected visually at least twice daily for evidence of ill-health or reaction to treatment.

BODY WEIGHT: Yes
- Time schedule for examinations: The weight of each male was recorded before dose administration, on the day that treatment commenced (Week 0), weekly throughout the treatment period and before necropsy. Females were weighed before dose administration, on the day that treatment commenced (Week 0), weekly until mating was detected, on Days 0, 6, 13 and 20 after mating and on Days 1, 4 and 7 of lactation.

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data

FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data

WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data

OPHTHALMOSCOPIC EXAMINATION: No data

HAEMATOLOGY: Yes
- Time schedule for collection of blood: During Week 2 (prior to pairing)
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes
- How many animals: the first five surviving males and females in each group

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: During Week 2 (prior to pairing)
- Animals fasted: Yes
- How many animals: the first five surviving males and females in each group

URINALYSIS: No data

NEUROBEHAVIOURAL EXAMINATION: No data

No additional data

Sacrifice and pathology:

GROSS PATHOLOGY: Yes, All external features and orifices were examined visually. After ventral mid-line incision, the neck and associated tissues and the thoracic, abdominal and pelvic cavities and their viscera were exposed and examined in situ. Any abnormal position, morphology or interaction was recorded.

HISTOPATHOLOGY: Yes

Other examinations:

None stated

Statistics:

None stated

Results and discussion

Results of examinations

Clinical signs:

no effects observed

Mortality:

no mortality observed

Body weight and weight changes:

no effects observed

Food consumption and compound intake (if feeding study):

no effects observed

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

not specified

Haematological findings:

no effects observed

Clinical biochemistry findings:

no effects observed

Urinalysis findings:

not specified

Behaviour (functional findings):

not specified

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Histopathological findings: non-neoplastic:

no effects observed

Histopathological findings: neoplastic:

not specified

Details on results:

CLINICAL SIGNS AND MORTALITY
One male receiving 100 mg/kg/day was found dead on Day 28 of treatment. There were no in-life findings prior to this animals death. Post mortem examination revealed a perforated oesophagus; the thorax contained clear fluid with pale adhesions, dark lungs and bronchi and reduced contents of the colon, ileum and caecum. This death was not considered related to treatment.
There were no signs recorded at routine observations or in association with dosing.

BODY WEIGHT AND WEIGHT GAIN
There were no dosage related effects of treatment upon male or female bodyweight.
Mean bodyweight and bodyweight gain was slightly higher for males receiving 300 mg/kg/day when compared with Controls. Overall bodyweight gain was slightly, but not statistically significantly higher for males receiving the test substance when compared with Controls, but no dose response was apparent.
During the pre-pairing phase mean bodyweight gain for females receiving the test substance up to 1000 mg/kg/day was slightly lower than that of the Control values, however, there was no dose response. Mean bodyweight and bodyweight gain was slightly higher during the gestation phase, but slightly lower than Controls during the lactation phase for females receiving the test substance.

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
Food consumption was considered not to be affected by treatment with the test substance up to 1000 mg/kg/day by males and females prior to pairing, during gestation and lactation when compared with Controls.
Group mean food intake was statistically significantly higher during Days 0-5 of gestation for females receiving 300 or 1000 mg/kg/day; however, this slight increase was of no biological importance.

HAEMATOLOGY
There were no consistent findings at haematological investigations to suggest any adverse dose response to treatment with the test substance. Haematological investigation in Week 2 of treatment revealed, occasional parameters which were statistically significantly different from Control but there was no clear biological significance of dosage relationship.

CLINICAL CHEMISTRY
The biochemical examination of the blood plasma in Week 2 of treatment detected no consistent changes suggestive of treatment related effect. Sporadic intergroup differences which appeared statistically significant included increased urea, creatinine and potassium levels in males and increased glucose levels in animals receiving 100 mg/kg/day when compared with Controls; in the absence of similar findings at higher doses a relationship to treatment is uncertain. Cholesterol and bile acids were lower in males receiving 1000 mg/kg/day when compared with Controls; there was no dose response for the cholesterol data and the bile acid data was highly variable.

ORGAN WEIGHTS
Organ weights were not obviously affected by treatment with the test substance, when compared with Controls.
Mean adjusted spleen weights were statistically significantly higher in males receiving 1000 mg/kg/day, when compared with Controls; this was not evident in the females

GROSS PATHOLOGY
The macroscopic examination of males after five weeks of treatment or on Day 7 of lactation revealed no intergroup differences.
The nature and incidence of all findings were consistent with the commonly seen background of macroscopic changes.

HISTOPATHOLOGY: NON-NEOPLASTIC
The following examined tissues had no findings microscopically:
Adrenals, Brain, Caecum, Colon, Duodenum, Epididymides, Eyes, Ileum, Jejunum, LN Mesenteric, Liver, Lt. LN Axillary, Mammary, Peyer's Patch, Prostate, Sciatic Nerve, Seminal Vesicles, Skeletal Muscle, Skin, Spinal C. Cerv., Spleen, Sternum + Marrow, Stomach, Thymus, Thyroids, Trachea, Urinary Bladder

No additional data

Effect levels

Key result

Dose descriptor:

NOAEL

Effect level:

1 000 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: no test substance related adverse effects observed up to and including 1000 mg/kg bw/day, the highest dose tested

Target system / organ toxicity

Critical effects observed:

not specified

Applicant's summary and conclusion

Conclusions:

It is concluded that oral administration of the test substance to Crl: CD (SD) rats for at least 5 weeks at doses of 100, 300 and 1000 mg/kg/day was well tolerated with no toxicologically significant systemic effects and there was no effect of treatment on reproductive performance, including mating performance, fertility and offspring survival and development up to Day 7 of age.
For general toxicity the no-observed-adverse-effect level (NOAEL) was considered to be 1000 mg/kg/day and for reproductive /developmental toxicity the no-observed-adverse-effect-level (NOAEL) was also considered to be 1000 mg/kg/day.